Safety outcomes by race and ethnicity in the real world
| n (%) . | Hispanic (n = 152) . | Non-Hispanic Asian (n = 78) . | Non-Hispanic Black (n = 68) . | Non-Hispanic White (n = 992) . |
|---|---|---|---|---|
| Any-grade CRS∗ | 123 (81) | 70 (90) | 56 (82) | 824 (83) |
| Grade ≥3 CRS | 7 (5) | 8 (10) | 4 (6) | 89 (9) |
| Any-grade ICANS | 65 (43) | 35 (45) | 27 (40) | 584 (59) |
| Grade ≥3 ICANS | 24 (16) | 16 (21) | 13 (19) | 285 (29) |
| Management of CRS and ICANS | ||||
| Tocilizumab | 94 (62) | 54 (69) | 38 (56) | 571 (58) |
| Corticosteroids | 55 (36) | 42 (54) | 19 (28) | 509 (51) |
| Prolonged cytopenia† | 37 (25) (n = 148) | 25 (36) (n = 70) | 13 (20) (n = 66) | 234 (24) (n = 957) |
| Neutropenia | 11 (7) | 5 (7) | 3 (5) | 67 (7) |
| Thrombocytopenia | 35 (24) | 23 (33) | 11 (17) | 215 (22) |
| n (%) . | Hispanic (n = 152) . | Non-Hispanic Asian (n = 78) . | Non-Hispanic Black (n = 68) . | Non-Hispanic White (n = 992) . |
|---|---|---|---|---|
| Any-grade CRS∗ | 123 (81) | 70 (90) | 56 (82) | 824 (83) |
| Grade ≥3 CRS | 7 (5) | 8 (10) | 4 (6) | 89 (9) |
| Any-grade ICANS | 65 (43) | 35 (45) | 27 (40) | 584 (59) |
| Grade ≥3 ICANS | 24 (16) | 16 (21) | 13 (19) | 285 (29) |
| Management of CRS and ICANS | ||||
| Tocilizumab | 94 (62) | 54 (69) | 38 (56) | 571 (58) |
| Corticosteroids | 55 (36) | 42 (54) | 19 (28) | 509 (51) |
| Prolonged cytopenia† | 37 (25) (n = 148) | 25 (36) (n = 70) | 13 (20) (n = 66) | 234 (24) (n = 957) |
| Neutropenia | 11 (7) | 5 (7) | 3 (5) | 67 (7) |
| Thrombocytopenia | 35 (24) | 23 (33) | 11 (17) | 215 (22) |
CRS was graded per Lee et al,19 and ICANS was graded per ASTCT consensus grading.17
ASTCT, American Society for Transplantation and Cellular Therapy; CRS, cytokine release syndrome; ICANS, immune effector cell–associated neurotoxicity syndrome.
Reported on the 100-day follow-up case-report form.
Defined as failure to resolve within the first 30 days after infusion, measured among patients who survived day 30 after infusion.